D'Amico D, Grazzi L, Usai S, Moschiano F, Bussone G
U.O. Cefalee e Malattie Cerebrovascolari, C. Besta National Neurological Institute, Via Celoria 11, I-20133, Milan, Italy.
Neurol Sci. 2005 May;26 Suppl 2:s130-3. doi: 10.1007/s10072-005-0425-6.
This paper reviews results of placebo-controlled trials on topiramate (TPM) prophylaxis in migraine patients, and discusses issues regarding the use of this medication in clinical practice. Data from well conducted double-blind controlled trials and from a comparative trial show that TPM is effective against migraine, confirming the experience of physicians in various countries. Lack of major contraindications, high responder rate, good tolerability at the target dose (100 mg/day) following slow titration, and lack of weight gain make TPM one of the most effective and well accepted drugs for migraine prophylaxis.
本文回顾了托吡酯(TPM)预防偏头痛患者的安慰剂对照试验结果,并讨论了该药物在临床实践中的使用问题。来自精心开展的双盲对照试验和一项对比试验的数据表明,TPM对偏头痛有效,证实了各国医生的经验。缺乏主要禁忌症、高有效率、在缓慢滴定后目标剂量(100毫克/天)时耐受性良好以及不导致体重增加,使得TPM成为预防偏头痛最有效且最易被接受的药物之一。